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CORRESPONDENCE
Letters to the Editor
Peak Oxygen
Consumption and Heart
Failure Prognosis in Women
There is nothing new except what has been forgotten
Marie Antoinette (1)
We read with interest the recent study by Elmariah et al. (2) as well
as the intriguing editorial by Feldman (3) regarding potential
genetic factors to explain gender differences in heart failure (HF)
prognosis. Elmariah et al. (2) demonstrated that peak oxygen
consumption (VO2) was significantly lower in women with HF
than in men and that this cardiopulmonary variable did not predict
HF prognosis or the need for cardiac transplantation as well in
women as it did in men. We firmly agree with this assessment and
have made this point (although in a smaller number of women) in
several publications during the past decade, sources not cited in
their excellent study (4–9).
Although our initial observations were made nearly 10 years ago
in a small sampling of women with HF (4), we subsequently sorted
this issue out in more detail by noting that higher body fat is an
independent predictor of better HF prognosis, which may partly
explain the well-recognized “obesity paradox” (7,8,10–13). Be-
cause women typically have considerably higher levels of percent
body fat and, for practical purposes, fat weight is not aerobically
active, it would make sense that VO2 corrected for total body
weight would be lower in groups of patients with higher body fat
(e.g., women and more obese patients) (5–9,11,13,14). However, if
one adjusts peak VO2 for lean body mass as opposed to total
weight, both genders and obese versus lean patients have more
similar functional capacities, and this assessment allows for more
accurate determination of HF prognosis (5,6,8,9,13). We have
most recently demonstrated that peak O2 pulse (peak VO2/peak
heart rate) adjusted for lean body mass was even slightly superior to
peak VO2 corrected for lean body mass for HF prognostication (6).
Therefore, we agree with these investigators that this evidence
must be considered when cardiopulmonary metabolic parameters
are used for prognostic stratification of women with HF (4–6,9).
Furthermore, a simple and very inexpensive determination of
percent body fat by the sum of the skin-fold method (or using
more sophisticated and expensive techniques such as dexa scanning
or underwater weighing) and correcting VO2 or O2 pulse for lean as
opposed to total weight should substantially improve the accuracy
of cardiopulmonary testing for HF stratification, particularly in
women and in other groups of patients with higher percent body
fat. Finally, although in some situations complex mechanisms are
involved, we believe that this is an example of where one may often
reach for complex explanations for findings when in fact the simple
explanation may be staring us in the face!
As Edward R. Murrow noted: “The obscure we see eventually.
The completely obvious, it seems, takes longer” (15).
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Reply
We appreciate the letter by Dr. Lavie and colleagues in
reference to our report on the effects of gender on the
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prognostic value of peak oxygen consumption (VO2) in heart
failure (HF) patients (1). Lavie and colleagues present an
interesting theory that the superior survival in female HF
patients may be due to their higher body fat content. Although
a plausible assumption at first glance, we controlled for several
important variables in our study population to account for body
fat composition. First, body mass index (BMI), a reliable
surrogate for body fat content (2), was equivalent between
genders in our study. Regardless of this, to address Lavie’s
concerns, we reanalyzed our data to correct for body composi-
tion. As skin-fold measurements were not performed on our
patients, we adjusted peak VO2 values to “ideal body weight,” as
calculated using the Wasserman formulae (3). We found that
the gender difference in peak VO2 persisted: peak VO2/ideal
body weight  16.5  5.7 ml/kg/min in women and 18.7  7.9
ml/kg/min in men (p  0.002). Thus, higher percent body fat
does not explain the lower peak VO2 or improved survival in
female HF patients.
Although Dr. Lavie and colleagues speculate that the difference
in body fat composition accounts for the gender differences in
exercise capacity in HF patients, it is clear that the mechanisms for
gender differences are much more complex. For example, myocar-
dium responds differently between the genders to stresses such as
increased afterload (4–6), and data suggest that this may be due to
hormonal influences on regulation of vasculature and myocardial
responses (6,7). Additionally, sudden cardiac death, which ac-
counts for approximately 40% of HF deaths, occurs less frequently
in women, potentially explaining their prolonged survival (8).
Given the complex HF pathophysiology, multiple factors are likely
responsible for the observed gender difference beyond just body fat
composition. We hope our study will encourage additional re-
search into the mechanism of gender differences in HF so that the
best treatment decisions can be made and the best therapies can be
applied to all patients.
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Atrial Fibrillation and Clinical
Events in Chronic Heart Failure
The study by Olsson et al. (1) found that atrial fibrillation (AF) is
associated with a worse outcome in patients with heart failure
(HF) regardless of whether HF is associated with depressed or
relatively preserved ventricular function, although those with
preserved left ventricular (LV) function had better survival than
did those with depressed LV function. In a series of 478 patients
hospitalized with AF and HF we observed that those with
preserved LV function had a similarly poor prognosis as did those
with depressed LV function when adjusted for age, gender,
coronary artery disease, and comorbid illness (2).
Differences in these findings might be illuminating. Whereas
the CHARM (Candesartan in Heart failure-Assessment of Re-
duction in mortality and morbidity) program enrolled stable HF
patients, our study population were patients who had a deteriora-
tion necessitating hospitalization. We observed a steep increase in
mortality shortly after the index hospitalization, suggesting that
such an event is a potent marker for mortality warranting aggres-
sive management. We also found an association between decreased
mortality and statin therapy, intriguing in view of recent speculation
that inflammation and fibrosis may be involved in promoting AF. It
would be of interest to know whether intercurrent development of AF
had a different prognosis as compared to pre-existing AF in CHARM
and whether statin therapy disproportionately affects outcomes.
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Drs. Parkash and Stevenson relate that in their experiences the
survival of patients with both atrial fibrillation (AF) and heart
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